Коксиб

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Коксиб

What is Coxib?

Coxib (generic name: celecoxib) is a pharmaceutical medication belonging to a specific class of nonsteroidal anti-inflammatory drugs (NSAIDs) known as selective COX-2 inhibitors. It is primarily utilized to manage symptoms associated with various inflammatory conditions and pain-related disorders.

Mechanism of Action

The medication works by targeting a specific enzyme in the body called cyclooxygenase-2 (COX-2). This enzyme is responsible for the production of prostaglandins, which are lipid compounds that trigger inflammation, fever, and pain signals. Unlike traditional NSAIDs that inhibit both COX-1 and COX-2 enzymes, coxibs are designed to be more selective, focusing primarily on the inflammatory enzyme while having a lesser impact on the enzyme that protects the stomach lining.

Primary Uses

Coxib is commonly used in clinical settings for the long-term and short-term management of several conditions, including:

  • Osteoarthritis: Relief of the signs and symptoms of degenerative joint disease.
  • Rheumatoid Arthritis: Management of chronic inflammatory autoimmune disorders affecting the joints.
  • Ankylosing Spondylitis: Treatment of inflammatory arthritis affecting the spine and large joints.
  • Acute Pain: Management of short-term pain, such as that following surgical procedures or injury.
  • Menstrual Pain: Alleviation of discomfort associated with primary dysmenorrhea.

Pharmacological Properties

By reducing the concentration of systemic prostaglandins, the medication helps decrease joint swelling, stiffness, and physical discomfort. Because of its selective nature, it is often considered for individuals who require anti-inflammatory therapy but have specific considerations regarding gastrointestinal sensitivity to non-selective pain relievers.

What side effects are possible with Коксиб?

Possible side effects and safety information

Regulatory documentation outlines the official safety profile of Celecoxib (the active ingredient in Коксиб) by classifying adverse reactions based on frequency and affected physiological system.

Adverse Reaction Classifications

Adverse reactions are grouped according to standard regulatory frequency categories derived from clinical trial and post-marketing data. These include Common effects, such as Hypertension, Peripheral Edema, and various Gastrointestinal symptoms (e.g., abdominal pain, dyspepsia, flatulence). Less frequent but officially listed events are classified as Uncommon or Rare.

Key systems affected, as classified in official System-Organ-Classes (SOCs), include the Gastrointestinal, Cardiovascular, Renal and Urinary, and Nervous systems.

Serious Adverse Reactions (SARs)

Official labeling emphasizes the potential for serious adverse reactions, which include major Cardiovascular Thrombotic Events such as Myocardial Infarction and Stroke. The drug is also associated with a risk of serious Gastrointestinal events, including Ulceration, Bleeding, or Perforation, which can occur at any time during treatment.

Rare but serious risks include severe Hepatic reactions and severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS).

Regulatory Safety Considerations

The risk of serious cardiovascular events may increase with the duration of use. Safety restrictions note that the medicine is contraindicated in patients with a known sulfonamide allergy, established ischemic heart disease, cerebrovascular disease, or severe hepatic or renal impairment. Specific safety notes apply to older adults (65 years), who face an increased risk of serious gastrointestinal events.

Overdose and Emergency Response

The official regulatory profile for an overdose of Коксиб (Celecoxib) focuses on the potential for serious systemic toxicity following overexposure. Acute manifestations may include gastrointestinal effects such as nausea, vomiting, epigastric pain, and neurological effects like drowsiness and lethargy.

Regulatory documents underscore the risk of serious systemic outcomes, which include acute renal failure and hepatic failure, severe gastrointestinal complications such as bleeding or ulceration, and the potential for serious cardiovascular thrombotic events like myocardial infarction or stroke.

In an overdosage situation, regulatory statements confirm that no specific antidote is known for celecoxib. Therefore, treatment is explicitly defined as symptomatic and general supportive measures. Authorities advise that managing a suspected overdose requires contacting a regional Poison Control Centre.

Immediate medical attention is required upon the manifestation of severe hypersensitivity reactions, such as signs of anaphylaxis (difficulty breathing or swelling of the face or throat). Due to the potential for delayed organ toxicity, patient monitoring may be necessary, and measures such as the prompt administration of activated charcoal for gastric decontamination may be considered.

Therapeutic Uses of Коксиб

What Коксиб Treats: Main Uses and Benefits

Коксиб is relevant for the sustained management of symptoms linked to major chronic inflammatory conditions that affect the joints. The medication is commonly used to help relieve the persistent pain, tenderness, swelling, and stiffness that are characteristic of these long-term diseases. This therapeutic use provides supportive relief that assists with maintaining functional stability and generally contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Symptom Management Focus

Therapeutic Scope Symptoms related to inflammatory or irritative states.
Key Benefit Supports maintenance of functional stability and comfort.
Typical Contexts Conditions involving chronic discomfort and acute or recurrent episodes.

The medication is commonly used to help manage symptoms across conditions such as Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, and pain associated with Primary Dysmenorrhea. It is also applied in clinical settings that involve acute or unstable symptom patterns and discomfort. It is applied during phases of increased distress or discomfort to offer symptomatic relief, which may assist with maintaining a sense of stability when symptoms are more noticeable.

The medication is also applied for managing the symptoms of Juvenile Idiopathic Arthritis (JIA) in pediatric patients.

Eligibility and Restrictions for Use

Коксиб (Celecoxib) is strictly defined by regulatory documents for use only in specific populations. The medicine is permitted for use in adults for its labeled indications and in pediatric patients 2 years of age and older specifically for Juvenile Idiopathic Arthritis (JIA).

The medicine is contraindicated in several mandatory exclusion groups. This includes individuals with a known hypersensitivity to celecoxib or sulfonamides, or those who have experienced serious allergic-type reactions to aspirin or other NSAIDs. It is also prohibited for treating pain following Coronary Artery Bypass Graft (CABG) surgery.

Category Official Regulatory Statement
Contraindicated Conditions Prohibited in those with severe hepatic impairment (Child-Pugh Class C), severe renal insufficiency, established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, or active inflammatory bowel disease (EMA SmPC).
Age and Gestational Status Contraindicated for use in children under 2 years of age. Contraindicated in pregnant women starting at 30 weeks of gestation; use is not recommended during lactation (FDA Label; EMA SmPC).
Use Restrictions Patients with moderate hepatic impairment and CYP2C9 poor metabolizers require reduced maximum daily doses. Use in older adults (65 years and older) requires caution (FDA Label; EMA SmPC).

The official eligibility profile requires that patients with moderate hepatic impairment and those who are CYP2C9 poor metabolizers be managed under restricted use with necessary dosage reduction. Caution is also advised when the medicine is used in older adults.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific co-administration constraints based on the documented interaction profile of [Коксиб]. Concomitant use with certain medicinal products requires dose adjustment, close monitoring, or avoidance.

Documented Interaction Categories

Product Category Interacting Agents (Examples) Constraint Type
Anticoagulants Warfarin Requires intensive INR monitoring
Antihypertensives ACE Inhibitors, ARBs, Diuretics May reduce efficacy; monitoring required
Other NSAIDs Other COX-2 Inhibitors, NSAIDs Concomitant use should be avoided
Cytotoxic/Immunosuppressants Methotrexate, Lithium, Ciclosporin Increased toxicity risk; monitoring/dose adjustment required
CYP2C9 Inhibitors Fluconazole Increases [Коксиб] exposure; caution advised

Key Interaction Implications

Co-administration with Warfarin requires close, mandatory surveillance of the patient's anticoagulation status (INR) due to increased bleeding risk. The drug may lessen the blood pressure-lowering effects of certain antihypertensive medicines (ACE inhibitors, ARBs, and Beta-blockers) and may decrease the effect of diuretics. Use with low-dose Aspirin (for cardioprotection) is generally permitted, but co-administration with high-dose, anti-inflammatory doses of Aspirin or other systemic NSAIDs is generally restricted or advised against. Concomitant use with Lithium or Methotrexate increases the systemic concentrations of these co-administered drugs, necessitating clinical monitoring and possible dosage modification of the interacting medicine.

Mechanism of Action

Selective COX-2 Enzyme Blockade

The fundamental mechanism of Коксиб (Celecoxib) is the targeted inhibition of the Cyclooxygenase-2 (COX-2) enzyme. This enzyme is chiefly responsible for synthesizing prostanoid mediators at sites of induction. By preferentially binding to a unique pocket on the COX-2 structure, the drug halts the initial step of the Arachidonic Acid Cascade , leading to a targeted action on the inducible signaling pathway.

Disruption of Prostaglandin Synthesis

The COX-2 blockade leads to the disruption of the Arachidonic Acid Cascade, specifically suppressing the production of potent mediators, primarily Prostaglandin E2 (PGE2). The resulting suppression of these signaling molecules modulates downstream physiological effects. This mechanism modulates nociceptive signaling and influences central hypothalamic thermoregulation.

Mechanistic Constraint on Vascular Homeostasis

While selective for COX-2, the mechanism carries a constraint due to the enzyme's role in normal functions. The drug suppresses COX-2-derived Prostacyclin (PGI2) in the endothelium while sparing the COX-1-derived Thromboxane A2 (TXA2) in platelets. The resulting physiological imbalance shifts the balance of the endothelial-platelet pathway toward vasoconstrictive and pro-aggregatory states.

Dosage and Administration Information

How to Use Коксиб — Administration Guidelines

Коксиб (celecoxib) is a medication administered via the oral route as a capsule. The standardized approach to using the medicine requires employing the lowest effective dosage for the shortest duration necessary for clinical management, with periodic re-evaluation of the usage pattern.


Administration Scope

Instruction Administration Rules
Route of administration Oral (capsule form).
Dosing schedule (Adult) Osteoarthritis (OA): 200 mg once daily (QD) or 100 mg twice daily (BID). Rheumatoid Arthritis (RA): 100 mg to 200 mg twice daily (BID). Maximum Daily Dose: 400 mg for all chronic conditions.
Timing in relation to meals May be taken with or without food for doses up to 200 mg BID. Higher doses should be taken with food.
Preparation requirements Capsule contents may be mixed with a level teaspoon of applesauce and swallowed immediately for patients with difficulty ingesting the capsule.
Age-group rules Pediatric (JIA): Dosing is weight-based for patients two years and older. Hepatic Impairment: A 50% dose reduction is required for those with moderate hepatic impairment.
Course duration Therapeutic need for chronic conditions, such as ankylosing spondylitis (AS), should be reassessed after a specified duration, such as 6 weeks.

Procedural Structure

The usage protocol establishes the precise quantity, frequency, and conditions for ingestion. The dose selected must correspond to the specific indication (OA, RA, or Acute Pain) and must not exceed the maximum daily allowance. Where applicable, the dose must be adjusted for reduced liver function or for pediatric patients according to weight-based scales. These instructions govern the entire usage cycle, from initial administration to continuous management.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Коксиб

This overview describes the types of official research that have been conducted on Коксиб (celecoxib) and what those studies have explored, focusing on the evidence structure without providing clinical advice or treatment instructions.


Evidence for Symptom Management in Osteoarthritis and Rheumatoid Arthritis

The research landscape exploring the role of Коксиб in chronic joint conditions includes Randomized Controlled Trials (RCTs), where study participants are randomly assigned to receive the study medicine, an active comparator, or a placebo (inactive pill). This method is used in research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA).

For OA, studies were primarily short-term, typically lasting between 6 and 12 weeks. The primary metrics examined included patient-reported changes in pain intensity and scores on standardized functional measures that assess stiffness and physical ability. These trials monitored outcomes related to daily functioning and activity level. Findings describe patterns observed in the studies related to measured outcomes in pain scores and function assessments over these short study periods. For RA, studies explored the medicine in adults, including those already taking other long-term disease therapies. Evidence suggests that measurements of symptomatic outcomes related to physical discomfort were observed in some studies.

Research on Ankylosing Spondylitis

The evidence base for Ankylosing Spondylitis (AS) includes intermediate-term RCTs. This research focused on conditions involving periods of heightened symptoms and monitored outcomes related to systemic or functional imbalance. Specifically, studies explored metrics designed to assess disease activity and functional status over defined time intervals.


Evidence for Use in Acute Inflammatory Conditions

Research has explored Коксиб in studies related to acute or disruptive episodes, such as certain types of sudden pain and Primary Dysmenorrhea. The studies conducted for acute pain were typically very short-term, sometimes involving only a single dose. Researchers examined outcomes describing episodic or acute changes, such as how quickly patients noticed a change in pain intensity and the total amount of relief reported over a few hours.


Research in Pediatric Patients (Juvenile Idiopathic Arthritis)

Коксиб was studied in specific RCTs and comparative trials for Juvenile Idiopathic Arthritis (JIA) in pediatric patients 2 years of age and older. Studies monitored outcomes related to daily functioning and activity level, including counts of active joints and overall assessments of well-being provided by parents and physicians. The results apply only to the populations studied—pediatric patients 2 years and older—as data for younger children are still emerging or limited.


Research Gaps and Areas of Uncertainty

The body of research also highlights areas where more data is needed or where results are less certain. Follow-up durations were limited for the primary efficacy assessments in most chronic pain conditions; therefore, evidence is limited regarding the maintenance of symptomatic changes and long-term function patterns. Subgroup findings are uncertain, as most pivotal trials included defined populations and did not extensively study patients with specific pre-existing conditions. Studies help show what has been observed so far, but the research does not determine whether an individual will respond similarly to the group patterns described in the trials.

Frequently Asked Questions (FAQ)

Common questions about Коксиб (FAQ)


Q: Is Коксиб considered a narcotic or opioid?

According to official regulatory documents, Коксиб is classified as a nonsteroidal anti-inflammatory drug (NSAID). Specifically, it belongs to the subclass of selective COX-2 inhibitors, which is a class of medicine separate from narcotics and opioids.


Q: How does the name 'Коксиб' relate to its use?

The name relates directly to the medicine's mechanism of action. Official pharmacological texts describe Коксиб as a selective inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme, and this class of drugs is often referred to as a 'coxib.' This targeted action is the basis for its therapeutic use in inflammation and pain.


Q: Is there a generic version of Коксиб available?

Yes, Коксиб is a trade name for the active ingredient celecoxib. The active substance celecoxib is available in generic form, according to information from major regulatory bodies.


Q: How quickly does Коксиб typically start to work for pain?

Clinical pharmacology data provides information on how the drug is processed by the body. Studies indicate that the medicine typically reaches its highest concentration in the bloodstream approximately 3 hours after a patient takes the capsule.


Q: How long does the effect of one dose of Коксиб usually last?

The duration of the drug's presence in the body is described by its half-life, which is approximately 11 hours in healthy adults. This half-life is the information that informs its usual prescription schedule for once or twice daily dosing.


Q: Is it common for people to take Коксиб every day for long periods?

The medicine is indicated for the management of chronic conditions such as rheumatoid arthritis and osteoarthritis. Official regulatory guidelines recommend using the lowest effective dose for the shortest duration necessary for all uses. The need for continued long-term use should be periodically reassessed.


Q: Can Коксиб affect my blood pressure?

Official labeling lists Hypertension (high blood pressure) as a common adverse reaction associated with the medication. The medicine is also associated with a risk of causing new-onset hypertension or worsening blood pressure control in patients who already have the condition.


Q: Are there any signs of a serious reaction to Коксиб I should know about?

Official patient information includes warnings regarding serious Cardiovascular Thrombotic Events. These documents describe symptoms such as chest pain, sudden shortness of breath, unexplained weakness, or slurred speech that are associated with these events.


Q: Can I take other pain medicines, like Tylenol (acetaminophen), with Коксиб?

Official drug interaction information generally advises against combining Коксиб with other NSAIDs or full-dose aspirin. While acetaminophen is not known to interact directly with celecoxib, official guidance indicates that individuals with a known NSAID or aspirin hypersensitivity require cautious use.


Q: What other common medications or supplements should not be taken with Коксиб?

Regulatory documents include warnings against co-administration with other NSAIDs and full-dose aspirin, and list potential interactions with Warfarin (an anticoagulant), Lithium, Methotrexate, and certain blood pressure medications like ACE inhibitors and ARBs.


Q: Does Коксиб interact with birth control pills?

Specific European regulatory labeling includes guidance regarding use during childbearing years. The official documentation states that the medicine is contraindicated in women who can become pregnant unless an effective method of contraception is used.


Q: Why are there warnings about kidney function for people taking Коксиб?

The warnings relate to the mechanism of the drug. NSAIDs can reduce the synthesis of prostaglandins in the kidneys, which are essential compounds that help maintain appropriate blood flow to the organ.


Q: Are there different strengths or dosages of Коксиб available?

Yes, official regulatory documents confirm that the capsules are available in different strengths. These commercially available options include 50 mg, 100 mg, 200 mg, and 400 mg capsules.


Q: What are common reasons someone might be asked to switch from a different NSAID to Коксиб?

Коксиб is a selective COX-2 inhibitor, meaning its mechanism is designed to spare the COX-1 enzyme. Because the COX-1 enzyme is primarily involved in protecting the stomach lining, this selectivity is linked to a distinct gastrointestinal safety profile compared to non-selective NSAIDs.


Q: Does taking Коксиб affect blood clotting?

Official warnings state that the medicine may reduce the anti-platelet effect of low-dose aspirin used for cardioprotection. When taken with other anticoagulants (blood thinners) like Warfarin, the co-administration requires careful surveillance of the patient's coagulation status due to an increased risk of bleeding.


Q: Does Коксиб cause water retention or swelling?

Yes, official labeling lists fluid retention and Peripheral Edema (swelling of the hands, ankles, or feet) among the reported adverse reactions. Peripheral Edema is specifically classified as a common side effect of the medicine.


Q: Is Коксиб different from traditional pain relievers like ibuprofen or aspirin?

Yes, Коксиб is officially categorized as a selective COX-2 inhibitor, whereas ibuprofen and aspirin are non-selective NSAIDs. This means Коксиб acts differently by primarily targeting the COX-2 enzyme involved in inflammation, rather than both COX-1 and COX-2.


Q: What are the main risks associated with long-term use of Коксиб?

Regulatory documents contain serious warnings stating that the risk of major Cardiovascular Thrombotic Events (such as heart attack and stroke) may increase with the duration of use. Similarly, the risk of serious gastrointestinal events, including ulceration and bleeding, also increases over time.


Q: Can Коксиб cause drowsiness or make me feel dizzy?

Drowsiness and dizziness are listed among the potential adverse effects in official drug information. These effects have also been reported as symptoms in cases of overdose.


Q: What should I do if I think I am having a side effect from Коксиб?

Official regulatory patient information includes descriptions of symptoms suggestive of a serious adverse event, such as chest pain, difficulty breathing, or unusual bruising. The documents define which adverse events require professional evaluation.


Q: Is Коксиб used to treat migraines or headaches?

While the general capsule form of Коксиб may not be indicated for general headaches, one specific oral solution formulation of the active ingredient, celecoxib, is approved for the acute treatment of migraine attacks in adults.


Q: What does official research say about the effectiveness of Коксиб for arthritis?

Clinical trial summaries describe that research examined measured outcomes related to symptomatic relief. Specifically, studies tracked patient-reported changes in pain intensity, stiffness, and physical function scores over defined periods in patients with rheumatoid arthritis and osteoarthritis.


Q: Does official labeling describe Коксиб as having any potential for dependence?

The medication is not classified as a controlled substance by regulatory authorities. Official labeling and warnings do not include information about physical or psychological dependence associated with its use.


Q: Does the drug have any known interactions with herbal supplements like St. John's wort?

Yes, some regulatory information notes that co-administration with St. John's wort may reduce the blood levels of celecoxib. This reduction in the medicine's concentration could potentially reduce its therapeutic effectiveness.


Q: What does official guidance say about stopping Коксиб before surgery?

The official labeling does not provide general guidance on stopping the drug before all surgeries. However, it is strictly contraindicated for treating pain immediately before or after Coronary Artery Bypass Graft ( CABG) surgery.


Q: What information do official labels provide about overusing Коксиб?

Official labeling warns against exceeding the maximum prescribed dosage. Symptoms reported in cases of overdose may include breathing difficulties, drowsiness, high blood pressure, and stomach pain or bleeding.


Q: Is Коксиб described as safe for people with asthma?

The medicine is strictly contraindicated in patients with aspirin-sensitive asthma due to the risk of severe, life-threatening allergic reactions. The official regulatory restriction applies specifically to this sub-population.


Q: What if I take two doses of Коксиб too close together?

Regulatory guidance emphasizes that the official maximum daily dose should not be exceeded. Taking doses too close together increases the risk of exceeding this limit, which can heighten the chances of experiencing serious side effects.


Q: Is Коксиб prescribed for post-surgery pain relief?

The use of Коксиб is strictly prohibited for pain relief following Coronary Artery Bypass Graft ( CABG) surgery. However, the medicine may be indicated for other specific acute pain conditions.


Q: Are there different brand names for the same medicine, Коксиб?

Yes, Коксиб is a brand name, and the active ingredient is celecoxib. This substance is sold under several other different trade names internationally, as is common with many prescription medicines.

How should Коксиб be stored and disposed of?

How to Store and Dispose of Коксиб (Celecoxib)

Official regulatory documents define specific conditions for storing and disposing of Коксиб (Celecoxib) capsules to maintain product quality and safety.

Required Storage Conditions

  • Temperature: Store at Controlled Room Temperature, 25 C (77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F).
  • Container: Keep the medicine in the container it came in and keep the container tightly closed.
  • Environment: Store away from excess heat and moisture, such as the bathroom.
  • Child Safety: The medication must be kept out of the sight and reach of children and pets, secured with a locked safety cap.

Stability and Disposal

When the capsule contents are mixed with soft food, the mixture is stable for up to 6 hours only when stored under refrigerated conditions. Unused or expired medication must be discarded via an authorized drug take-back program or by following household trash procedures: mix the contents with an undesirable substance, seal it in a bag, and place it in the trash. Do not flush this medicine down the toilet or pour it down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Коксиб found in:

A-Z Index: